The Cavadis pipeline contains a series of novel biomarkers in various phases of development. Individual markers and multi-marker panels are selected for developing prognostic tests for cardiovascular indications, including myocardial infarction (MI), stroke, and peripheral artery disease (PAD).
Read more

Traditional risk factors such as cholesterol and high blood pressure are insufficient to adequately assess the risk for cardiovascular events, while the search for new biomarkers especially in the field of secondary prevention is rather unexplored. Hence, a high need exists for diagnostic tests identifying high-risk populations.
Read more

Immunoassays for cardiovascular biomarkers are expected to grow at an average growth rate of 23% to $4.5 billion in 2012. The cardiovascular segment will grow twice as fast as two other major segments cancer and infectious diseases, making it the leading category in 2012.


Read more

A fundamental shift in drug development strategies is taking place. Traditionally the focus of pharmaceutical companies was on a small portfolio of "blockbuster" products based on epidemiological studies in large patient cohorts. Nowadays, the trend is towards creating a host of more targeted therapies with higher efficacy in smaller patient groups.
Read more